Mammals express four Notch receptor paralogs (Notchi -4) that have been implicated in a broad range of functions during embryogenesis, post-natal development, and vartous pathologies, including cancer. As a result, there is growing interest in therapies aimed at blocking or activating Notch signaling in specific cellular or pathological contexts. During the previous funding period, we explored the spectrum of effects triggered by loss of Notchi activity with a novel genetic approach combining a knock-in Notchi allele (Nl ::CreLo), in which Cre replaced the NICD, and a conditional Notchi target allele (Niflox). The trans-heterozygous animals (Nl :CreLo/flox) were bred to reporter mice developed in the Molecular Reporter Core which contained floxed-stop click beetle red luciferase and dual reporter (lac-Z or eYFP) genes on respective alleles downstream ofthe ROSA26 locus. A systematic, life-long in vivo screen with bioluminescence imaging of animals wherein a random, progressive and age-dependent Notchi loss occurred identified a role for Notchi in suppressing neoplasia ofthe vascular system. Our findings caution against the Genetech approach of therapies targeting Notchi and provide a model in which to assess strategies to delay, prevent or control vascular tumor formation and thereby widen the therapeutic window of anti-Notch therapies. We will examine age, diet and organ dependence in vascular tumor formation using new Nl ::CreERT2 alleles permitting temporal control over loss of Notchi. We will use another new Notch trans-heterozygous combination, N2::CreLo/flox, to monitor risks associated specifically with loss of Notch2. An additional benefit from the proposed experiments will be a detailed map of all stem cell compartments where Notchi and Notch2 maintain stemness or promote differentiation. These studies will ultimately lead to safer Notch- targeting therapies.

Public Health Relevance

Unique trans-heterozygous animals (N1/2:CreLo/flox) bred to molecular imaging reporter mice will be used for life-long in vivo screens with bioluminescence imaging and MRI to study age-dependent roles for Notch in suppressing neoplasias of the vascular system.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRLB-9)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Washington University
Saint Louis
United States
Zip Code
Black, Kvar C L; Akers, Walter J; Sudlow, Gail et al. (2015) Dual-radiolabeled nanoparticle SPECT probes for bioimaging. Nanoscale 7:440-4
Kocher, Brandon A; White, Lynn S; Piwnica-Worms, David (2015) DAPK3 suppresses acini morphogenesis and is required for mouse development. Mol Cancer Res 13:358-67
Alspach, Elise; Flanagan, Kevin C; Luo, Xianmin et al. (2014) p38MAPK plays a crucial role in stromal-mediated tumorigenesis. Cancer Discov 4:716-29
Nickless, Andrew; Jackson, Erin; Marasa, Jayne et al. (2014) Intracellular calcium regulates nonsense-mediated mRNA decay. Nat Med 20:961-6
Choi, Jaebok; Cooper, Matthew L; Alahmari, Bader et al. (2014) Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect. PLoS One 9:e109799
Garg, Gunjal; Gibbs, Jesse; Belt, Brian et al. (2014) Novel treatment option for MUC16-positive malignancies with the targeted TRAIL-based fusion protein Meso-TR3. BMC Cancer 14:35
Hensley, Harvey; Devarajan, Karthik; Johnson, James R et al. (2014) Evaluating new therapies in gastrointestinal stromal tumor using in vivo molecular optical imaging. Cancer Biol Ther 15:911-8
Garg, Gunjal; Vangveravong, Suwanna; Zeng, Chenbo et al. (2014) Conjugation to a SMAC mimetic potentiates sigma-2 ligand induced tumor cell death in ovarian cancer. Mol Cancer 13:50
Rauch, Daniel A; Harding, John C; Ratner, Lee (2014) IL-15 deficient tax mice reveal a role for IL-1? in tumor immunity. PLoS One 9:e85028
Elhammali, Adnan; Ippolito, Joseph E; Collins, Lynne et al. (2014) A high-throughput fluorimetric assay for 2-hydroxyglutarate identifies Zaprinast as a glutaminase inhibitor. Cancer Discov 4:828-39

Showing the most recent 10 out of 185 publications